NASDAQ · XRAY
Healthcare · Medical - Instruments & Supplies
$11.59
Up+$0.01 (+0.09%)
Updated Aug 15, 2026, 4:12 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XRAY closed at $11.59 after 21 trading sessions, down 17.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $11.50 | $11.88 | $11.46 | $11.59 | 2.71M |
| Aug 13, 2026 | $11.44 | $11.69 | $11.28 | $11.58 | 3.3M |
| Aug 12, 2026 | $11.48 | $11.7536 | $11.215 | $11.41 | 7.61M |
| Aug 11, 2026 | $11.63 | $11.96 | $11.56 | $11.61 | 4.14M |
| Aug 10, 2026 | $12.08 | $12.12 | $11.63 | $11.66 | 5.74M |
| Aug 7, 2026 | $13.36 | $13.578 | $12.01 | $12.12 | 8.57M |
| Aug 6, 2026 | $13.92 | $13.98 | $13.08 | $13.17 | 5.51M |
| Aug 5, 2026 | $14.19 | $14.19 | $13.69 | $13.78 | 3.65M |
| Aug 4, 2026 | $14.04 | $14.35 | $13.92 | $14.27 | 4.3M |
| Aug 3, 2026 | $13.74 | $14.17 | $13.65 | $14.13 | 7.15M |
| Jul 31, 2026 | $13.62 | $13.74 | $13.185 | $13.37 | 3.63M |
| Jul 30, 2026 | $14.22 | $14.365 | $13.39 | $13.74 | 3.94M |
| Jul 29, 2026 | $13.42 | $14.435 | $13.42 | $14.20 | 5.64M |
| Jul 28, 2026 | $13.19 | $13.54 | $13.1106 | $13.49 | 4.79M |
| Jul 27, 2026 | $13.02 | $13.265 | $12.885 | $13.02 | 4.06M |
| Jul 24, 2026 | $12.97 | $13.13 | $12.73 | $12.93 | 3.96M |
| Jul 23, 2026 | $13.15 | $13.24 | $12.345 | $12.72 | 7.75M |
| Jul 22, 2026 | $13.87 | $14.04 | $13.12 | $13.27 | 4.94M |
| Jul 21, 2026 | $13.20 | $13.715 | $13.20 | $13.65 | 5.29M |
| Jul 20, 2026 | $13.96 | $14.01 | $13.395 | $13.46 | 4.87M |
| Jul 17, 2026 | $13.78 | $14.095 | $13.7003 | $14.05 | 6.07M |
The latest Smart Investors Daily articles mentioning XRAY.
XRAY research
Company profile and research snapshot.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | Piper Sandler | Neutral | — |
| Jul 9, 2026 | BMO Capital | Market Perform | — |
| Jun 4, 2026 | Barclays | Underweight | — |
| May 7, 2026 | UBS | Buy | — |
| May 6, 2026 | Mizuho | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 11, 2026
Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast.
Yahoo · Aug 7, 2026
DENTSPLY SIRONA (NASDAQ:XRAY) reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europ
Yahoo · Aug 7, 2026
Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per share from...
Yahoo · Aug 7, 2026
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XRAY.
